The first nine patients have completed the Phase 1 clinical trial of CYT-108, with no reported adverse events. This biologic therapy aims to treat osteoarthritis by targeting cartilage-degrading enzymes. The company plans to initiate Phase 2 trials and will launch an equity crowdfunding campaign to finance further development.
As 2024 ends, Cytonics reflects on remarkable progress in developing their drug CYT-108 for osteoarthritis treatment. The first clinical trial began, greatly aided by a team of orthopedic specialists. Plans for Phase 2 trials are underway, with fundraising efforts expected in early 2025 to support research and development.
